SS Innovations Celebrates Nasdaq Debut and Milestone Surgeries

SS INNOVATIONS INTERNATIONAL INC: Company Profile and Developments

SS Innovations International Inc. (Nasdaq: SSII) is a medical technology company specializing in robotic-assisted surgery. Founded in 2015 by Dr. Sudhir Srivastava, who holds records in robotic beating-heart coronary bypass procedures, the firm is headquartered in Fort Lauderdale, Florida, with significant operations and R&D in Gurugram, India. Its flagship product, the SSi Mantra surgical robotic system, is designed for multi-specialty applications—including cardiothoracic, urology, gynecology, and general surgery—with a focus on affordability and accessibility.

Corporate Structure and Leadership

With between 201 and 500 employees, SS Innovations employs engineers, scientists, and clinicians dedicated to advancing surgical robotics. Dr. Sudhir Srivastava serves as Founder, Chairman, and Chief Executive Officer, overseeing both clinical strategy and product development. On May 1, 2025, the company appointed Arvind Palaniappan as Interim Chief Financial Officer. Mr. Palaniappan is a Chartered Accountant with over 30 years of financial and operational experience; Anup Sethi, the former CFO, remains available in an advisory role until a permanent successor is appointed.

Recent Developments and News

• 2,000 Procedures Milestone (September 23, 2024)
  SS Innovations reported the completion of over 2,000 robotic surgeries, including 123 cardiac cases, primarily in India using the SSi Mantra. The milestone highlights the system’s deployment in Tier 2 and Tier 3 Indian cities, as well as its first installation in Nepal.

• Uplisting to Nasdaq (April 25, 2025)
  The company’s common shares began trading on the Nasdaq stock exchange under the ticker SSII, transitioning from OTC to a major U.S. market.

• Chief Financial Officer Transition (May 1, 2025)
  Arvind Palaniappan was named Interim CFO, initiating a search for a permanent financial leader following seven years of service by departing CFO Anup Sethi.

• Opening Bell at Nasdaq MarketSite (June 3, 2025)
  Dr. Srivastava rang the Opening Bell in Times Square to commemorate SS Innovations’ Nasdaq debut and improve the company’s visibility among investors.

• Industry Conferences and Outreach

  • At the ISMICS Annual Conference in Istanbul (May 28–31, 2025), Dr. Srivastava delivered the Kit V. Arom Lecture, discussing his transition from cardiac surgery to medical robotics.
  • LinkedIn updates feature international training initiatives and highlight a robotic cardiac surgery performed in Guayaquil, Ecuador, utilizing the SSi Mantra.

• SEC Filings (June 2, 3, and 16, 2025)
  SS Innovations filed three Form 8-K current reports covering Items 7.01, 8.01, and 9.01. These filings confirm compliance and various corporate events; however, detailed financial and operational data are available in the full EDGAR documents.

Financial and Strategic Analysis

Stock Data (as of June 20, 2025):

• Price: USD 7.53
• Daily Change: +54.30%
• Volume: 296,114 shares
• Exchange: Nasdaq (Ticker: SSII)

SS Innovations aims to capture underserved market segments with its cost-effective robotic platform. The SSi Mantra features a modular, multi-arm design; an open-console ergonomic command center; 3D 4K visualization; and a suite of over 40 specialized instruments. The company is pursuing regulatory approvals in the United States (FDA) and the European Union (CE Mark) with the expectation of obtaining clearances in the second half of 2025. The company's growth strategy includes geographic expansion, partnerships with hospitals in emerging markets, and enhancements such as intraoperative holographic anatomy, telesurgery over 5G, and AI-driven workflow assistants.

Market Position and Industry Context

The global surgical robotics market is characterized by established players, yet high acquisition and maintenance costs may limit adoption in resource-constrained settings. SS Innovations differentiates itself through affordability, modular scalability, and targeted deployment in Tier 2 and Tier 3 cities and emerging economies. Its emphasis on surgeon training—through on-site didactics, proctoring, and continuous support—aims to facilitate clinical acceptance. As demand for minimally invasive procedures increases worldwide, SS Innovations positions the SSi Mantra as a potentially more accessible alternative, aligning with healthcare systems that seek to manage costs while incorporating advanced technology.

tl;dr

On May 1, 2025, SS Innovations appointed Arvind Palaniappan as Interim Chief Financial Officer, following its uplisting to Nasdaq (SSII) on April 25. The company rang the Opening Bell on June 3 and has completed over 2,000 robotic surgeries using its SSi Mantra system. With FDA and CE Mark submissions underway, clearance is expected in the second half of 2025 to support global expansion into underserved markets.